MediaRX® Community

Welcome to the MediaRX® Community—a place where healthcare industry leaders, policy makers, clinicians, companies, influencers, and brands connect with the shared interest of using media to amplify their voices. Dive into digital storytelling, spark conversations, and discover fresh strategies to engage audiences. 

We encourage you to introduce yourself and let us know what you're looking forward to getting out of this community. Whether it's seeking advice, sharing insights, professional networking or simply making new friends, we're excited to see the contributions you'll bring to our vibrant community

The U.S. Food & Drug Administration (FDA) has approved Lynkuet (elinzanetant), the first dual neurokinin-1/3 (NK1/NK3) receptor antagonist, as a hormone-free treatment for moderate-to-severe hot flashes and night sweats due to menopause.

This milestone marks a major advancement in women’s health and is a timely reminder that nurses, especially women clinicians, must be at the forefront of telling these stories

Interested in learning how you can use media to amplify your voice?

Check out our latest newsletter to learn more. https://wix.to/MoE6uh0

2026 MediaRX Academy starts April 6, 2026. 

Learn more ➡️ https://www.themediarx.com/academy

https://www.drnurseimelda.com/

Still needs some editing but it's coming along.

Cheers,

Imelda